ASCO GI 2026

January 08-10, 2026
San Francisco, CA

ASCO Gastrointestinal Cancer Symposium 2026

Explore more Oncology congress materials

Results(2)

Oncology

Landmark Analysis of Overall Survival by Objective Response in Patients With Previously Treated, Advanced HER2-Positive Biliary Tract Cancer: Post Hoc Analysis of the HERIZON-BTC-01 Trial

Author(s): James J Harding, Jia Fan, Do-Youn Oh et al.

Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01

Author(s): Elena Elimova, Sun Young Rha, Kohei Shitara et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.